

Name of journal: World Journal of Gastroenterology

ESPS Manuscript NO: 13294

Columns: Meta-Analysis

Value² of bevacizumab in the treatment of colorectal cancer: a meta-analysis

Chun-Ying Qu, Ying Zheng, Min Zhou, Yi Zhang, Feng Shen, Jia Cao, Lei-Ming Xu

Abstract

AIM: To assess the efficacy and safety of bevacizumab in the treatment of colorectal cancer.³

METHODS: All randomized controlled trials of bevacizumab for the treatment of colorectal cancer from January 2003 to June 2013 were collected by searching the Cochrane Library, PubMed, Chinese National Knowledge Infrastructure (CNKI) and Wanfang databases. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), overall response rate (ORR) and adverse events (AEs). Two reviewers extracted data independently. Statistical analyses were performed with Stata 12.0. The degree of bias was assessed using funnel plots

Match Overview

1	CrossCheck 30 words Vishal Ranpura. "Increased Risk of High-Grade Hyperten ... on With Bevacizumab in Cancer Patients: A Meta-Analysis",	1%
2	CrossCheck 22 words A Dewdney. "Correlation of bevacizumab-induced hyperten sion and outcome in the BOXER study, a phase II study of c	1%
3	Internet 21 words crawled on 24-Apr-2014 www.docstoc.com	1%
4	CrossCheck 10 words Macromolecular Anticancer Therapeutics, 2010.	<1%